Boston Scientific Corporation has announced significant executive changes that will shape the company’s leadership structure moving forward. Joe Fitzgerald, currently the Executive Vice President and Group President of Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer, effective January 1, 2027. This appointment is crucial as the company continues to navigate the competitive landscape of the surgical and medical instruments industry.
Fitzgerald has been with Boston Scientific since 1990, holding various leadership roles within the Cardiovascular sector. His promotion comes at a time when the company aims to enhance its operational efficiency and innovation in heart therapies. “Joe’s extensive experience and proven track record in our Cardiovascular business make him the ideal choice to lead our operations,” said the company’s board in a statement.
In addition to Fitzgerald's promotion, the company has appointed Mark Bickel as Senior Vice President, Global Accounting Controller and Chief Accounting Officer, effective March 1, 2027. Bickel, who currently serves as Senior Vice President, Finance and Global Controller of the Cardiovascular business, will transition into this new role while continuing to support the company’s financial strategies.
Boston Scientific is a leading player in the surgical and medical instruments sector, focusing on developing advanced technologies for healthcare professionals and patients globally. The company operates on the New York Stock Exchange under the ticker symbol BSX and is categorized under SIC 3841, which covers surgical and medical instruments and apparatus.
The recent filing with the SEC, accession number 0000885725-26-000064, outlines the details of these leadership changes. Fitzgerald will receive a base salary of $1,050,000, along with participation in the company's Annual Bonus Plan, which has an incentive target equal to 110% of his salary. He will also be granted an annual equity award valued at $7 million, further aligning his interests with the company’s long-term growth.
Meanwhile, Bickel’s appointment is seen as a strategic move to bolster the company’s financial oversight as it continues to expand its market presence. His background in finance and experience within the company’s operations are expected to contribute positively to Boston Scientific’s financial health.
Both Fitzgerald and Bickel are expected to play pivotal roles in steering the company through upcoming challenges and opportunities in the medical technology field. The leadership transitions reflect Boston Scientific's commitment to maintaining a robust executive team capable of driving the company’s strategic initiatives.
Looking ahead, Boston Scientific is poised to continue its focus on innovation and operational excellence under the new leadership. The filing does not specify any further actions or upcoming votes related to these changes, but the company is expected to communicate additional details as the effective dates approach.